Table 5.

The clinical trials of CAR-NK cell-based therapy for hematological malignancies and solid tumors

Cancer type	ClinicalTrials.gov Identifier	Initial time	Phase	N	Primary study endpoint
R/R Non-Hodgkin Lymphoma	NCT04639739 CD19	December 17, 2020	Phase I	9	Incidence of dose limiting toxicity Incidence and severity of AEs and SAEs
Relapsed and Refractory B Cell Lymphoma	NCT03692767 CD22	March 2019	Phase I	9	Occurrence of treatment related adverse events as assessed by CTCAE v4.0
Relapsed and Refractory B Cell Lymphoma	NCT03690310 CD19	March 2019	Phase I	9	Occurrence of treatment related adverse events as assessed by CTCAE v4.0
Epithelial Ovarian Cancer	NCT03692637 Mesothelin	March 2019	Phase I	30	Occurrence of treatment related adverse events as assessed by CTCAE v4.0
metastatic Solid Tumours	NCT03415100 NKG2D-ligand	January 2, 2018	Phase I	30	Number of Adverse Events
Castration-Resistant Prostate Cancer	NCT03692663 PSMA	December 2018	Phase I	9	Occurrence of treatment related adverse events as assessed by CTCAE v4.0
Solid Tumors	NCT03940820 ROBO1	May 2019	Phase I/II	20	Occurrence of treatment related adverse events as assessed by CTCAE v4.03
Relapse/Refractory MM	NCT03940833 BCMA	May 2019	Phase I/II	20	Occurrence of treatment related adverse events as assessed by CTCAE v4.03
Recurrent/Metastatic Gastric or Head and Neck Cancer	NCT04847466 Irradiated PD-L1	April 22, 2021	Phase II	55	ORR
Relapsed and Refractory B Cell Lymphoma	NCT03824964 CD19/CD22	February 1, 2019	Phase I	10	Occurrence of treatment related adverse events as assessed by CTCAE v4.0
B Lymphoid Malignancies	NCT04796675 CD19	April 10, 2021	Phase I	27	Incidence of Treatment-related Adverse Events
Relapsed/Refractory CD33 + AML	NCT02944162 CD33	October 2016	Phase I/II	10	Adverse events attributed to the administration of the anti-CD33 CAR-NK cells
CD19 Positive Leukemia and Lymphoma	NCT02892695 CD19	September 2016	Phase I	10	Adverse events attributed to the administration of the anti-CD19 CAR-NK cells
Pancreatic Cancer	NCT03941457 ROBO1	May 2019	Phase I	9	Occurrence of treatment related adverse events as assessed by CTCAE v4.03
CD19 + Relapsed/Refractory Hematological Malignancies	NCT04796688 CD19	March 10, 2021	Phase I	27	Incidence of Treatment-related Adverse Events
Relapsed/Refractory B-Lymphoid Malignancies	NCT03056339 CD19	June 21, 2017	Phase I/II	36	Toxicity and efficacy